J&J outlines $5.5bn talc settlement plan

Generic talc powder containers on a clinical counter amid legal settlement news over product safety

Key Points

01J&J proposes a $5.5 billion resolution of ovarian talc lawsuits
02Plan is aimed at covering tens of thousands of federal and state claims
03Settlement requires participation from firms representing at least 95% of claims
04First payment capped at $3 billion in 2027, none due before 2028

J&J proposes multibillion-dollar talc settlement

Johnson & Johnson (JNJ) has agreed to a proposed resolution that would commit $5.5 billion to settle litigation alleging that its talc products caused ovarian cancer. The proposed package is designed as an efficient conclusion to lawsuits that have accumulated over many years in U.S. courts. The plan is structured around per-claim payments to eligible plaintiffs rather than a single lump-sum distribution.

Reports on the scope of the proposal indicate that it is intended to cover a very large majority of remaining talc-related claims. Several accounts state that about 69,000 cases consolidated in federal court in New Jersey, along with related state-court cases, would be included. This group is described as representing approximately 99.75% of outstanding talc claims tied to ovarian cancer allegations.

Conditions attached to the proposed resolution

The settlement framework includes specific participation thresholds before it can be implemented. Johnson & Johnson (JNJ) has said the agreement requires the involvement of lead plaintiff firms representing at least 95% of remaining ovarian talc claimants. Only if that level of participation is achieved would the proposed resolution move forward toward completion.

Timing of the payments is also clearly defined in the company’s outline. Under the plan, the first payment would be no more than $3 billion and is scheduled for 2027. No additional payments would be due under the proposal before 2028, which spreads the financial impact over multiple years rather than concentrating it in the near term.

Ongoing denial of liability and product changes

While advancing the settlement proposal, Johnson & Johnson (JNJ) maintains that its talc products did not cause cancer. The company continues to deny that its hallmark baby powder and other talc-based products were harmful. Plaintiffs in the litigation have alleged that the talc products were contaminated with asbestos, which the company disputes.

Separately from the legal negotiations, Johnson & Johnson has already altered its product lineup in response to the talc controversy. The company stopped selling talc-based Johnson’s Baby Powder in the United States in 2020. It subsequently ended global sales of talc-based baby powder in 2023, marking a complete exit from talc-based baby powder markets worldwide.

Key Takeaways

01The proposed $5.5 billion plan is structured to resolve nearly all remaining ovarian talc claims, but it depends on high levels of plaintiff participation.
02Clear timing and caps on initial payments indicate a staged financial impact, with the largest outlay not expected until 2027.
03Johnson & Johnson is pairing its settlement efforts with a full exit from talc-based baby powder, while still contesting the underlying allegations of harm.

References